Tue, Jul 29, 2014, 6:06 AM EDT - U.S. Markets open in 3 hrs 24 mins

Recent

% | $
Click the to save as a favorite.

Vical Incorporated Message Board

  • exceededmydosage exceededmydosage Apr 14, 2009 6:35 PM Flag

    NVAX Flu Vaccine

    NVAX announced today a successful preclinical trial of a VLP vaccine against the killer Spanish Flu. This same vaccine also showed protection against the deadly Vietnam strain of avian flu. Their press release says that this cross-strain protection makes this a great candidate for a pandemic stockpile.

    This may be a bit presumptuous however.

    Gardisil is a VLP vaccine and requires careful temperature monitoring or it can be catastrophically degraded...and even when refrigerated it only has a shelf-life of 3 years...also VLP vaccines must never be frozen.

    Plasmid vaccines are stable at room temperature and Vical is doing an ongoing study of stored frozen plasmids which so far have gone past 5 years without any loss of efficacy. Total shelf-life is still unknown.

    Since both vaccines may provide crucial cross-strain protection, which do you think is the better candidate for emergency stockpiling?

    Here's an article from Oct. 2008 where Vijay and NVAX's CEO make their case for why their pandemic flu approach is superior. Vijay emphasizes shelf-life while NVAX boasts that VLP's don't require "dangerous" adjuvants like Vaxfectin. Personally I think Vaxfectin is only dangerous to NVAX's bottom line!

    http://laboratorian.advanceweb.com/article/avian-immunity.aspx

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • As I'm writing this Vical is up 30% in the premarket and NVAX is up 175% so I guess NVAX wins the PR battle even if Vical has the better technology. While Vijay deserves some praise for getting the naked DNA rights for influenza back from Merck he should also realize that public relations is also extremely important if you want to get your stock price up before raising more working capital by issuing new shares.

    • Best Article ever!

      NVAX announced today a successful preclinical trial of a VLP vaccine against the killer Spanish Flu. This same vaccine also showed protection against the deadly Vietnam strain of avian flu. Their press release says that this cross-strain protection makes this a great candidate for a pandemic stockpile.

      This may be a bit presumptuous however.

      Gardisil is a VLP vaccine and requires careful temperature monitoring or it can be catastrophically degraded...and even when refrigerated it only has a shelf-life of 3 years...also VLP vaccines must never be frozen.

      Plasmid vaccines are stable at room temperature and Vical is doing an ongoing study of stored frozen plasmids which so far have gone past 5 years without any loss of efficacy. Total shelf-life is still unknown.

      Since both vaccines may provide crucial cross-strain protection, which do you think is the better candidate for emergency stockpiling?

      Here's an article from Oct. 2008 where Vijay and NVAX's CEO make their case for why their pandemic flu approach is superior. Vijay emphasizes shelf-life while NVAX boasts that VLP's don't require "dangerous" adjuvants like Vaxfectin. Personally I think Vaxfectin is only dangerous to NVAX's bottom line!

      http://laboratorian.advanceweb.com/artic...

    • Very informative. Thanks.

    • Wrong Board This is VICL

 
VICL
1.27+0.02(+1.60%)Jul 28 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.